Clinical Trials · NCT02870231
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 187
- Start date
- Aug 2016
- Locations
- 2 sites, United States
- Primary endpoint
- Number of treatment emergent adverse events